Venkys (India) to set up a new veterinary drug manufacturing plant

Venkys (India) is setting up a new manufacturing project for veterinary medicine products as part of its animal health products segment. The company acquired land with an area of ​​15030 m² in MIDC, village: Kesurdi, Tal: Khandala, district: Satara, Maharashtra for this purpose.

Construction activities will begin in December 2021 and the project is expected to be completed by March 2022 and commercial production to begin by June 2022.

This project consists in manufacturing veterinary drug powders (600 tons / year) and veterinary drug liquids (300 kiloliters per year) to meet the growing demand of the poultry industry.

The total cost of the project is estimated at Rs. 30 crore which will be financed by internal regularizations.

The proposed plant will be the company’s second and will comply with the latest FDA regulations and is expected to meet export needs as well. The Company already has a factory located in Pune (Maharashtra) with a capacity of 600 tons / year and said capacity is 70-80% utilized.

Powered by Capital Market – Live News

(This story was not edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear reader,

Business Standard has always strived to provide up-to-date information and commentary on developments that matter to you and have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these difficult times resulting from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative views and cutting-edge commentary on relevant current issues.
However, we have a demand.

As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with more quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of providing you with even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital editor

Source link

About Alex S. Crone

Check Also

2021 Regenerative Medicine Products Market Size Analysis by Major Companies

New Jersey, United States, – Market Research Intellect has been analyzing the technology and markets …